化疗诱导周围神经病变(CIPN)的临床与临床前视角:叙述性综述
该叙述性综述更新了化疗诱导周围神经病变(CIPN)的临床与临床前认识。临床部分涵盖评估、诊断与治疗,指出约30%患者化疗后症状持续,缺乏有效预防策略,度洛西汀有中等证据。临床前部分讨论动物模型及线粒体功能障碍、氧化应激、免疫细胞和离子通道等机制。
要点
- 约30%患者化疗后CIPN症状持续,影响功能与生活质量。
- 尚无有效预防CIPN的策略,度洛西汀治疗已有CIPN证据中等。
- CIPN多种机制并存且相互强化,可能需联合治疗。
核心结论
- CIPN常可缓解但约30%患者问题持续,缺乏有效预防策略且治疗证据有限。
- 需加强肿瘤与疼痛管理团队协作以有效监测CIPN患者。
- 临床与临床前研究持续合作有助于开发CIPN新疗法。
研究设计与样本
- 叙述性综述,总结CIPN当前临床与临床前认识。
主要发现
- 紫杉醇、奥沙利铂、硼替佐米等常用化疗药可引起CIPN。
- 严重CIPN可能需减量或停用化疗,影响患者生存。
- 约30%患者化疗后CIPN问题持续,影响功能与生活质量。
- 临床前模型提示线粒体功能障碍、氧化应激、免疫细胞及离子通道改变等可调机制。
- 多种因果机制同时发生或相互强化,提示联合治疗可能更有效。
关键数值与推荐
- 度洛西汀治疗已有CIPN有中等证据,其他神经病理性疼痛状态的治疗经验常被外推用于指导CIPN治疗。
- 尚无有效预防CIPN的策略。
临床怎么用
- 早期评估和诊断CIPN很重要,应使用为此开发的工具。
- 治疗CIPN可参考度洛西汀的中等证据及其他神经病理性疼痛的治疗经验。
- 肿瘤与疼痛管理团队应紧密协作,确保CIPN患者得到有效监测。
局限性
- 为叙述性综述,未报告系统检索策略。
- 缺乏有效预防策略,治疗已确立CIPN的有效药物证据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This review provides an update on the current clinical and preclinical understanding of chemotherapy induced peripheral neuropathy (CIPN). The overview of the clinical syndrome includes a review of its assessment, diagnosis and treatment. CIPN is caused by several widely-used chemotherapeutics including paclitaxel, oxaliplatin, bortezomib. Severe CIPN may require dose reduction, or cessation, of chemotherapy, impacting on patient survival. While CIPN often resolves after chemotherapy, around 30% of patients will have persistent problems, impacting on function and quality of life. Early assessment and diagnosis is important, and we discuss tools developed for this purpose. There are no effective strategies to prevent CIPN, with limited evidence of effective drugs for treating established CIPN. Duloxetine has moderate evidence, with extrapolation from other neuropathic pain states generally being used to direct treatment options for CIPN. The preclinical perspective includes a discussion on the development of clinically-relevant rodent models of CIPN and some of the potentially modifiable mechanisms that have been identified using these models. We focus on the role of mitochondrial dysfunction, oxidative stress, immune cells and changes in ion channels from summary of the latest literature in these areas. Many causal mechanisms of CIPN occur simultaneously and/or can reinforce each other. Thus, combination therapies may well be required for most effective management. More effective treatment of CIPN will require closer links between oncology and pain management clinical teams to ensure CIPN patients are effectively monitored. Furthermore, continued close collaboration between clinical and preclinical research will facilitate the development of novel treatments for CIPN.
引用
- Flatters SJL, Dougherty PM, Colvin LA, et al. Clinical and preclinical perspectives on Chemotherapy-Induced Peripheral Neuropathy (CIPN): a narrative review. Br J Anaesth. 2017. PMID: 29121279. doi:10.1093/bja/aex229
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。